Dupilumab efficacy and safety up to 2 years in children aged 6 months to 5 years with atopic dermatitis

被引：0
|
作者：
Paller, Amy S. [1 ,2 ]
Simpson, Eric L. [3 ]
Siegfried, Elaine C. [4 ,5 ]
Cork, Michael J. [6 ,7 ]
Arkwright, Peter D. [8 ]
Pinter, Andreas [9 ]
Dubost-Brama, Ariane [10 ]
Laws, Elizabeth [11 ]
Chen, Zhen [12 ]
Bansal, Ashish [12 ]
Prescilla, Randy [11 ]
Nguyen, Tien, V [13 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] St Louis Univ, St Louis, MO USA
[5] Cardinal Glennon Childrens Hosp, St Louis, MO USA
[6] Univ Sheffield, Sheffield Dermatol Res, Sheffield, England
[7] Sheffield Childrens Hosp, Sheffield, England
[8] Univ Manchester, Manchester, England
[9] Univ Hosp Frankfurt Main, Frankfurt, Germany
[10] Sanofi, Chilly Mazarin, France
[11] Sanofi, Cambridge, MA USA
[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[13] Regeneron Pharmaceut Inc, Los Angeles, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; pediatric; long-term; safety; dupilumab;
D O I：
10.1093/bjd/ljae266.075
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
701
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [21] Mid-Term Efficacy of Dupilumab in Children Aged > 36 Months to <12 Years With Atopic Dermatitis: A Case Series
    Ramos, F. J. Melgosa
    Corpas, T. Diaz
    Jimenez, S. Martin
    Puchades, A. Mateu
    ACTAS DERMO-SIFILIOGRAFICAS, 2024, 115 (06): : 625 - 627
  • [22] Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Praestgaard, Amy
    Prescilla, Randy
    Wang, Zhixiao
    Marco, Ainara Rodriguez
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB40 - AB40
  • [23] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Kroeller-Schoen, S.
    ALLERGOLOGIE, 2022, 45 (08) : 621 - 622
  • [24] Pharmacokinetics, safety, and efficacy of dupilumab in children aged ≥2 to &lt;6 years with severe uncontrolled atopic dermatitis (LIBERTY AD PRE-SCHOOL)
    Simpson, Eric L.
    Kamal, Mohamed Ahmed
    Davis, John D.
    Sun, Xian
    Gadkari, Abhijit
    Eckert, Laurent
    Rossi, Ana Beatris
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB19 - AB19
  • [25] Pharmacokinetics, safety and efficacy of dupilumab in children aged ≥ 2 to &lt; 6 years with severe, uncontrolled atopic dermatitis (LIBERTY AD PRE-SCHOOL)
    Simpson, E. L.
    Lockshin, B.
    Kamal, M.
    Davis, J. D.
    Sun, X.
    Gadkari, A.
    Rossi, A. B.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E95 - E96
  • [26] Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged 6 months-5 years and their caregivers
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Wollenberg, Andreas
    Arkwright, Peter D.
    Zhang, Haixin
    Wang, Zhixiao
    Marco, Ainara R.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E112 - E113
  • [27] Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis
    不详
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (02) : E39 - E39
  • [28] Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study
    Zhou, Xiyuan
    Yang, Ge
    Chen, Xuejun
    Zhang, Lixia
    DRUGS & AGING, 2023, : 933 - 940
  • [29] Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study
    Zhou, Xiyuan
    Yang, Ge
    Chen, Xuejun
    Zhang, Lixia
    DRUGS & AGING, 2023,
  • [30] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to &lt; 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
12345